Get email alerts on the Healthcare Insurance topic
No spam. Unsubscribe anytime.
Senate passes bill clarifying coverage for biomarker testing
Summary
Senate Bill 169, described as a cleanup to last year's biomarker law, requires coverage for biomarker tests when clinical utility is shown and limits conditioning coverage on unrelated laboratory credentialing; final passage recorded 35–0.
Senator Talbot described Senate Bill 169 as a technical cleanup to last year’s biomarker testing law and said the measure ‘‘just requires coverage for biomarker testing when clinical utility is demonstrated’’ and clarifies that coverage should not be conditioned on laboratory classifications unrelated to test performance.
The sponsor reported no opposition in committee. The Senate moved to final passage; the recorded machine vote was 35 yays, 0 nays and motions to reconsider were laid on the table without objection.
AI generated
The text on this page is AI generated. Summaries, highlights, analysis, and video transcripts are all produced from the original source material.
AI can make mistakes, so if you spot one, and we will fix it for everyone.
Note: the source content is unaltered by us. Any content source we link to, be it a video, an audio recording, or a document, is presented exactly as its publisher released it. That publisher is usually a government body, sometimes an individual official or another organisation.
